287 related articles for article (PubMed ID: 18644620)
1. Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma.
Olawaiye AB; Rauh-Hain JA; Withiam-Leitch M; Rueda B; Goodman A; del Carmen MG
Gynecol Oncol; 2008 Sep; 110(3):293-8. PubMed ID: 18644620
[TBL] [Abstract][Full Text] [Related]
2. Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma.
Rauh-Hain JA; Growdon WB; Schorge JO; Goodman AK; Boruta DM; McCann C; Horowitz NS; del Carmen MG
Gynecol Oncol; 2010 Nov; 119(2):299-304. PubMed ID: 20691465
[TBL] [Abstract][Full Text] [Related]
3. Role of cytoreduction in stage III and IV uterine papillary serous carcinoma.
Thomas MB; Mariani A; Cliby WA; Keeney GL; Podratz KC; Dowdy SC
Gynecol Oncol; 2007 Nov; 107(2):190-3. PubMed ID: 17825394
[TBL] [Abstract][Full Text] [Related]
4. Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease.
Bristow RE; Asrari F; Trimble EL; Montz FJ
Gynecol Oncol; 2001 May; 81(2):279-86. PubMed ID: 11330963
[TBL] [Abstract][Full Text] [Related]
5. The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma.
Bristow RE; Duska LR; Montz FJ
Gynecol Oncol; 2001 Apr; 81(1):92-9. PubMed ID: 11277657
[TBL] [Abstract][Full Text] [Related]
6. Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC).
Fields AL; Einstein MH; Novetsky AP; Gebb J; Goldberg GL
Gynecol Oncol; 2008 Jan; 108(1):201-6. PubMed ID: 17997145
[TBL] [Abstract][Full Text] [Related]
7. Treatment of early-stage uterine papillary serous carcinoma at Roswell Park Cancer Institute, 1992-2006.
Tchabo NE; McCloskey S; Mashtare TL; Andrews C; Singh AK; Mhawech-Fauceglia P; Odunsi K; Lele S; Jaggernauth W
Gynecol Oncol; 2009 Nov; 115(2):249-56. PubMed ID: 19692115
[TBL] [Abstract][Full Text] [Related]
8. Performance of serum CA125 as a prognostic biomarker in patients with uterine papillary serous carcinoma.
Gupta D; Gunter MJ; Yang K; Lee S; Zuckerwise L; Chen LM; Goldberg GL; Huang GS
Int J Gynecol Cancer; 2011 Apr; 21(3):529-34. PubMed ID: 21436701
[TBL] [Abstract][Full Text] [Related]
9. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy.
Kelly MG; O'malley DM; Hui P; McAlpine J; Yu H; Rutherford TJ; Azodi M; Schwartz PE
Gynecol Oncol; 2005 Sep; 98(3):353-9. PubMed ID: 16005947
[TBL] [Abstract][Full Text] [Related]
10. Preoperative CA-125 predicts extra-uterine disease and survival in uterine papillary serous carcinoma patients.
Roelofsen T; Mingels M; Hendriks JC; Samlal RA; Snijders MP; Aalders AL; Bulten J; van Ham MA; Massuger LF
Int J Biol Markers; 2012 Oct; 27(3):e263-71. PubMed ID: 22865295
[TBL] [Abstract][Full Text] [Related]
11. The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma.
Hamilton CA; Cheung MK; Osann K; Balzer B; Berman ML; Husain A; Teng NN; Kapp DS; Chan JK
Gynecol Oncol; 2006 Nov; 103(2):679-83. PubMed ID: 16793126
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: a phase II Hoosier Oncology Group (HOG 97-01) study.
Fakiris AJ; Moore DH; Reddy SR; Look KY; Yiannoutsos CT; Randall ME; Cardenes HR;
Gynecol Oncol; 2005 Mar; 96(3):818-23. PubMed ID: 15721431
[TBL] [Abstract][Full Text] [Related]
13. CA 125, NB/70K, and lipid-associated sialic acid in monitoring uterine papillary serous carcinoma.
Tseng PC; Sprance HE; Carcangiu ML; Chambers JT; Schwartz PE
Obstet Gynecol; 1989 Sep; 74(3 Pt 1):384-7. PubMed ID: 2761916
[TBL] [Abstract][Full Text] [Related]
14. Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer.
Chung HH; Kim JW; Park NH; Song YS; Kang SB; Lee HP
Acta Obstet Gynecol Scand; 2006; 85(12):1501-5. PubMed ID: 17260229
[TBL] [Abstract][Full Text] [Related]
15. Uterine papillary serous carcinoma: patterns of failure and survival.
Wang W; DO V; Hogg R; Wain G; Brand A; Bull C; Stenlake A; Gebski V
Aust N Z J Obstet Gynaecol; 2009 Aug; 49(4):419-25. PubMed ID: 19694700
[TBL] [Abstract][Full Text] [Related]
16. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN).
Goldberg H; Miller RC; Abdah-Bortnyak R; Steiner M; Yildiz F; Meirovitz A; Villà S; Poortmans PM; Azria D; Zidan J; Ozsahin M; Abacioglu U; Gold DG; Amit A; Lavie O; Atahan IL; Kuten A;
Gynecol Oncol; 2008 Feb; 108(2):298-305. PubMed ID: 18096209
[TBL] [Abstract][Full Text] [Related]
17. Outcomes in surgical stage I uterine papillary serous carcinoma.
Havrilesky LJ; Secord AA; Bae-Jump V; Ayeni T; Calingaert B; Clarke-Pearson DL; Berchuck A; Gehrig PA
Gynecol Oncol; 2007 Jun; 105(3):677-82. PubMed ID: 17355889
[TBL] [Abstract][Full Text] [Related]
18. The prognostic significance of thrombocytosis in uterine papillary serous carcinomas.
Lerner DL; Walsh CS; Cass I; Karlan BY; Li AJ
Gynecol Oncol; 2007 Jan; 104(1):91-4. PubMed ID: 16934317
[TBL] [Abstract][Full Text] [Related]
19. Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation.
Kelly MG; O'Malley D; Hui P; McAlpine J; Dziura J; Rutherford TJ; Azodi M; Chambers SK; Schwartz PE
Gynecol Oncol; 2004 Dec; 95(3):469-73. PubMed ID: 15581948
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors and treatment-related outcome in patients with uterine papillary serous carcinoma.
Sagr ER; Denschlag D; Kerim-Dikeni A; Stanimir G; Gitsch G; Gilbert L
Anticancer Res; 2007; 27(2):1213-7. PubMed ID: 17465265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
